The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine

Journal of Molecular Medicine

Volumn 74, Issue 3, 1996, Pages 143-147

  Gartenhaus, R B ^a   Wang, P ^a   Hoffman, M ^a   Janson, D ^a   Rai, K R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

2 CDA 2 Chlorodeoxyadenosine; CLL Chronic lymphocytic leukemia

Indexed keywords

CLADRIBINE; PROTEIN P53;

APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CLADRIBINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029881313     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01575446     Document Type: Article

References (24)

1. O'Brien S, del Giglio A, Keating M (1995) Advances in the biology and treatment of B-cell Chronic Lymphocytic Leukemia. Blood 85:307-318
2. Liepman M, Votaw ML (1978) The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 41:1664-1668
3. French Cooperative Group on Chronic Lymphocytic Leukemia (1990) A randomized clinical trial of chlorambucil versus COP in Stage B chronic lymphocytic leukemia. Blood 75: 1422-1427
4. Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W (1994) Clinical experience with fludarabine in leukemia. Drugs 47:39-44
5. Tallman M, Hakimian D, Variakojis (1992) A single cycle of 2-chlorodeoxyadenosine in the majority of patients with hairy cell leukemia. Blood 80:2203-2207
6. Carson DA, Wasson DB, Beutler E (1984) Antileukemic and immunosuppressive activity of 2-CDA. Proc Natl Acad Sci USA 81:2232-2236
7. Robertson L, Chubb S, Story M (1991) Induction of DNA cleavage in chronic lymphocytic leukemia cells by chlorodeoxydeadenosine and fludarabine. Proc Am Assoc Can Res 32:415
8. Huang MC, Ashmun RA, Avery TL (1986) Effects of cytotoxicity of 2-choro-2-deoxyadenosine and 2-bromo-2- deoxyadenosine on cell growth, clonogenicity, DNA synthesis and cell cycle kinetics. Cancer Res 46:2362-2368
9. El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAFI, a potential mediator of p53 tumor suppression. Cell 75:817-823
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge S (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of GI cyclin dependent kinases. Cell 75:805-812
11. Lowe SW, Ruley HE, Jacks T, Houseman DE (1993) p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-962
12. Cole SP (1986) Rapid chemosensitivity testing of human tumor cells using the MTT assay. Cancer Chemother Pharmacol 17:259-263
13. Gong J, Traganos F, Darzynkiewiez Z (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218: 314-318
14. Fan S, El Deiry W, Bae I, Freeman J, Jondle D, Bhatia K, Fornace Jr. AJ, Magrath I, Kohn KW, O'Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824-5828
15. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D (1994) Induction of WAF1/CIP1 by a p53 independent pathway. Cancer Res 54:3391-3396
16. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonvenux H, Vanrumbeke M, Sartiaux C, Morel P, LeFebevre MHL, Bauters F, Berger R, Kerckaert JP (1992) Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: A report on 39 cases with cytogenetic analysis. Leukemia 6:246-250
17. Gaidano G, Ballerini P, Gong J, Inghirami G, Neri A, Newcomb E, Magrath I, Knowles D, Dalla Favera R (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413-5418
18. Linzer DH, Levine AJ (1979) Characterization of a 54 kd cellular Sv-40 tumor antigen in Sv-40 transformed cells. Cell 17:43-50
19. Sarnow P, Ho YS, Williams J, Levine AJ (1982) Adenovirus Elb-58 kd tumor antigen and Sv-40 large antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387-393
20. Gartenhaus RB, Wang P, Hoffmann P. Induction of WAF1/CIP1 and apoptosis in HTLV-I transformed lymphocytes after treatment with Adriamycin using a p53 independent pathway. Proc Natl Acad Sci USA (in press)
21. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukoc Lymphoma 5:133
22. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD (1993) 2-Chlorodeoxyadenosine activity in patients with previously untreated chronic lymphocytic leukemia. Blood 82:445a
23. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 6:219-234
24. Dohner H, Fischer K, Benta M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P (1995) p53 gene deletion predicts for poor survival and non response to therapy with purine analogs in chronic B-CLL leukemias. Blood 85:1580-1589